Go Deep
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 22,668 | 34.6 | 5.55 | 0.03 | 232.49 |
| Oct 2026 | 22,350 | 34.5 | 5.53 | 0.03 | 231.73 |
| Oct 2026 | 21,721 | 33.6 | 5.40 | 0.03 | 225.60 |
Jagsonpal Pharmaceuticals Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 822,320,000.0 | 642,030,000.0 | 729,450,000.0 | 744,650,000.0 |
| Net Profit | 131,890,000.0 | 87,621,000.0 | 109,510,000.0 | 125,740,000.0 |
| EPS | 2.0 | 1.2 | 1.7 | 1.9 |
Jagsonpal Pharmaceuticals Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 2,872,250,000.0 | 2,687,160,000.0 | 2,087,020,000.0 | 2,367,140,000.0 | — |
| Net Profit | 430,820,000.0 | 553,611,000.0 | 224,630,000.0 | 267,210,000.0 | — |
| EPS | 6.4 | 8.3 | 3.4 | 4.1 | — |
Jagsonpal Pharmaceuticals Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 3,166,770,000.0 | 2,782,600,000.0 | 2,170,780,000.0 | 1,949,460,000.0 | — |
| Total Liabilities | 405,050,000.0 | 383,100,000.0 | 296,760,000.0 | 360,560,000.0 | — |
| Total Equity | 2,761,720,000.0 | 2,399,500,000.0 | 1,874,020,000.0 | 1,588,900,000.0 | — |
Owes vs Owns
Jagsonpal Pharmaceuticals Limited owed ₹0.13 for every ₹1 it owned in Mar 2026, down from ₹0.18 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.13× | 0.14× | 0.14× | 0.18× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Jagsonpal Pharmaceuticals Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 33.5%Receivables 5.4%Inventory 4.6%Fixed assets (tangible) 2.3%Intangible assets 24.6%Long-term investments 26.7%Other assets 2.8%
How it's funded — Mar 2026
Long-term debt 2.1%Payables 3.7%Other liabilities 6.6%Shareholders' equity 87.2%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 106.1 | 128.7 | 147.9 | 114.7 |
| Receivables | 17.2 | 13.2 | 11.0 | 20.9 |
| Inventory | 14.6 | 15.2 | 15.0 | 20.7 |
| Fixed assets (tangible) | 7.3 | 8.8 | 9.3 | 24.3 |
| Intangible assets | 78.0 | 85.6 | 0.0 | 0.0 |
| Long-term investments | 84.5 | 17.4 | 4.7 | 3.4 |
| Other assets | 8.9 | 9.3 | 29.2 | 11.0 |
| Liabilities & equity | ||||
| Short-term debt | 1.6 | 1.6 | 1.4 | 0.0 |
| Long-term debt | 6.6 | 7.6 | 7.6 | 5.2 |
| Payables | 11.6 | 9.7 | 7.6 | 16.6 |
| Other liabilities | 20.8 | 19.3 | 13.1 | 14.2 |
| Shareholders' equity | 276.2 | 239.9 | 187.4 | 158.9 |
| Net tangible assets | 198.2 | 154.3 | 187.4 | 158.9 |
Jagsonpal Pharmaceuticals Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 468,120,000.0 | 551,130,000.0 | 351,660,000.0 | 466,550,000.0 | — |
| Investing Activities | -356,490,000.0 | -451,470,000.0 | -245,480,000.0 | -576,710,000.0 | — |
| Financing Activities | -121,490,000.0 | -116,980,000.0 | -89,110,000.0 | -4,570,000.0 | — |